{"id":"408878e7-0750-51c0-b04d-fc93fabd30e9","stable_key":"7edf94bb-95c8-5234-9161-9eb338bb9b36:boron-fructoborate-womac","predicate":"reduces","statement":"The WOMAC treatment difference was −13.73 at day 14 (p<0.0001); the day-seven difference of −5.3 had p=0.06 and was not conventionally significant.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"fca73de4-84af-509c-87e8-cd4faab6d829","mechanism_event_label":"The combined knee symptom/function score improved at two weeks; the one-week result was uncertain.","subject":{"id":"ff3117ce-4dba-59de-a41c-dd181a43c42c","slug":"calcium-fructoborate","display_name":"Calcium fructoborate","entity_type_key":"small_molecule"},"object":{"id":"df274ec1-d39f-51cc-9f36-68a481dca6f4","slug":"knee-womac-score","display_name":"Knee symptoms and function assessed by WOMAC","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"fca73de4-84af-509c-87e8-cd4faab6d829","stable_key":"7edf94bb-95c8-5234-9161-9eb338bb9b36:boron-fructoborate-womac-event","event_type":"observed_intervention","label":"The combined knee symptom/function score improved at two weeks; the one-week result was uncertain.","description":"The WOMAC treatment difference was −13.73 at day 14 (p<0.0001); the day-seven difference of −5.3 had p=0.06 and was not conventionally significant.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"ff3117ce-4dba-59de-a41c-dd181a43c42c","slug":"calcium-fructoborate","display_name":"Calcium fructoborate","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"df274ec1-d39f-51cc-9f36-68a481dca6f4","slug":"knee-womac-score","display_name":"Knee symptoms and function assessed by WOMAC","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/boron-research/24940052.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be\", \"start_char\": 0, \"end_char\": 1393, \"text_sha256\": \"67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized placebo-controlled trial; 60 participants with self-reported knee discomfort","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Calcium fructoborate 110 mg twice daily for 14 days; compound mass is not elemental boron dose","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Short symptom trial. The 2021 correction (PMID 33564230, https://pubmed.ncbi.nlm.nih.gov/33564230/) disclosed FutureCeuticals funding/product supply, company employment and patent interests; the journal requested retrospective registration. Day-seven WOMAC p=0.06 was not conventionally significant despite broader wording in the original abstract. These are corrections/qualifications, not a new scientific conflict.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Boron research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"boron","display_name":"Boron","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The combined knee symptom/function score improved at two weeks; the one-week result was uncertain.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[boron-p24940052] Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study. (2014). https://pubmed.ncbi.nlm.nih.gov/24940052/ DOI: 10.2147/cia.s64590","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Pain and WOMAC questionnaire outcomes","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"38d59230-2077-57c0-99fb-a1ae1fb7647a","evidence_kind":"source_excerpt","locator":"Lines 1080-1091","start_line":1080,"end_line":1091,"excerpt":"### boron-fructoborate-womac\nThe WOMAC treatment difference was −13.73 at day 14 (p<0.0001); the day-seven difference of −5.3 had p=0.06 and was not conventionally significant.\nCondition category: normal\nnutrient_topic: Boron research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The combined knee symptom/function score improved at two weeks; the one-week result was uncertain.\norganism: Human\ntissue_or_cell_type: Pain and WOMAC questionnaire outcomes\nexperimental_model: Randomized placebo-controlled trial; 60 participants with self-reported knee discomfort\nlimitations: Short symptom trial. The 2021 correction (PMID 33564230, https://pubmed.ncbi.nlm.nih.gov/33564230/) disclosed FutureCeuticals funding/product supply, company employment and patent interests; the journal requested retrospective registration. Day-seven WOMAC p=0.06 was not conventionally significant despite broader wording in the original abstract. These are corrections/qualifications, not a new scientific conflict.\nexposure: Calcium fructoborate 110 mg twice daily for 14 days; compound mass is not elemental boron dose\nevidence_span: {\"source_cache\": \"artifacts/boron-research/24940052.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be\", \"start_char\": 0, \"end_char\": 1393, \"text_sha256\": \"67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be\"}\n[boron-p24940052] Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study. (2014). https://pubmed.ncbi.nlm.nih.gov/24940052/ DOI: 10.2147/cia.s64590","model_system":"Randomized placebo-controlled trial; 60 participants with self-reported knee discomfort","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [boron-p24940052] Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study. (2014). https://pubmed.ncbi.nlm.nih.gov/24940052/ DOI: 10.2147/cia.s64590","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2d96c547-aeec-5d8b-9d31-1288da209f89","stable_key":"import-7edf94bb-95c8-5234-9161-9eb338bb9b36","title":"Boron: chemistry, nutrient interactions, low-intake studies and mechanistic uncertainties (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"0a32c1c5c70cfb4a378f6ace35cf5b75d90ed3065ada91b9f9f64015d603c8e3","revision_id":"38f316f2-4344-542e-a638-0ac5402f678d","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}